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[57] ABSTRACT 
Peptide nucleic acids containing histidine moieties are pro 
vided. These compounds have applications including 
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HISTIDINE-CONTAINING PEPTIDE 
NUCLEIC ACIDS 
This application is a continuation of Ser. No. 09/069,705 
?led Apr. 29, 1998, and a provision of Ser. No. 60/051,002 
?led May 29, 1997. 
FIELD OF THE INVENTION 
The present invention is directed to histidine-containing 
peptide nucleic acids and to synthetic intermediates 
employed in preparing such compounds. 
BACKGROUND OF THE INVENTION 
Oligonucleotides and their analogs have been developed 
and used in molecular biology in certain procedures as 
probes, primers, linkers, adapters, and gene fragments. 
Modi?cations to oligonucleotides used in these procedures 
include labeling With non isotopic labels, e.g. ?uorescein, 
biotin, digoxigenin, alkaline phosphatase, or other reporter 
molecules. 
Other modi?cations have been made to the ribose phos 
phate backbone to increase the nuclease stability of the 
resulting analog. These modi?cations include use of methyl 
phosphonates, phosphorothioates, phosphorodithioate 
linkages, and 2‘-O-methyl ribose sugar units. Further 
modi?cations, include modi?cations made to modulate 
uptake and cellular distribution. Phosphorothioate oligo 
nucleotides are presently being used as antisense agents in 
human clinical trials for various disease states including use 
as antiviral agents. With the success of these oligonucle 
otides for both diagnostic and therapeutic uses, there exists 
an ongoing demand for improved oligonucleotide analogs. 
Oligonucleotides can interact With native DNA and RNA 
in several Ways. One of these is duplex formation betWeen 
an oligonucleotide and a single stranded nucleic acid. The 
other is triplex formation betWeen an oligonucleotide and 
double stranded DNA to form a triplex structure. 
In peptide nucleic acids, the deoxyribose backbone of 
oligonucleotides has been replaced With a backbone more 
akin to a peptide than a sugar. Each subunit, or monomer, 
has a naturally-occurring or non-naturally-occurring base 
attached to this backbone. One such backbone is constructed 
of repeating units of N-(2-aminoethyl)glycine linked 
through amide bonds. Because of the radical deviation from 
the deoxyribose backbone, these compounds Were named 
peptide nucleic acids (PNAs). 
PNAs bind both DNA and RNA to form PNA/DNA or 
PNA/RNA duplexes. The resulting PNA/DNA or PNA/RNA 
duplexes are bound With greater af?nity than corresponding 
DNA/DNA or DNA/RNA duplexes as indicated by melt 
temperatures. This high thermal stability might be attributed 
to the lack of charge repulsion due to the neutral backbone 
in PNA. The neutral backbone of the PNA also results in the 
melt temperatures of PNA/DNA(RNA) duplex being prac 
tically independent of the salt concentration. Thus the PNA/ 
DNA duplex interaction offers a further advantage over 
DNA/DNA duplex interactions Which are highly dependent 
on ionic strength. Homopyrimidine PNAs have been shoWn 
to bind complementary DNAor RNA forming (PNA)2/DNA 
(RNA) triplexes of high thermal stability (see, e.g., Egholm, 
et al., Science, 1991, 254, 1497; Egholm, et al., J. Am. 
Chem. Soc., 1992, 114, 1895; Egholm, et al., J. Am. Chem. 
Soc., 1992, 114, 9677). 
In addition to increased af?nity, PNAs have also been 
shoWn to bind to DNA With increased speci?city. When a 
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PNA/DNA duplex mismatch is melted relative to the DNA/ 
DNA duplex there is seen an 8 to 20° C. drop in the melt 
temperature This magnitude of a drop in Tm is not 
seen With the corresponding DNA/DNA duplex With a 
mismatch present. 
The binding of a PNA strand to a DNA or RNA strand can 
occur in one of tWo orientations. The orientation is said to be 
anti-parallel When the DNA or RNA strand in a 5‘ to 3‘ 
orientation binds to the complementary PNA strand such 
that the carboxyl end of the PNA is directed toWards the 5‘ 
end of the DNA or RNA and amino end of the PNA is 
directed toWards the 3‘ end of the DNA or RNA. In the 
parallel orientation the carboxyl end and amino end of the 
PNA are just the reverse With respect to the 5 ‘-3‘ direction of 
the DNA or RNA. 
PNAs bind to both single stranded DNA and double 
stranded DNA. As noted above, in binding to double 
stranded DNA it has been observed that tWo strands of PNA 
can bind to the DNA. While PNA/DNA duplexes are stable 
in the antiparallel con?guration, it Was previously believed 
that the parallel orientation is preferred for (PNA)2/DNA. 
The binding of tWo single stranded pyrimidine PNAs to a 
double stranded DNA has been shoWn to take place via 
strand displacement, rather than conventional triple helix 
formation as observed With triplexing oligonucleotides. 
When a PNA strand invades double stranded DNA, one 
strand of the DNA is displaced and forms a loop on the side 
of the PNAZ/DNA complex area. The other strand of the 
DNA is locked up in the (PNA)2/DNA triplex structure. The 
loop area (alternately referenced as a D loop) being single 
stranded, is susceptible to cleavage by enZymes that can 
cleave single stranded DNA. 
A further advantage of PNAs as compared to oligonucle 
otides is that their polyamide backbone (having appropriate 
nucleobases or other side chain groups attached thereto) is 
not recogniZed by either nucleases or proteases and are not 
cleaved. As a result PNAs are resistant to degradation by 
enZymes unlike nucleic acids and peptides. 
These properties of PNAs make them useful in several 
areas. Since PNAs have stronger binding and greater speci 
?city than oligonucleotides, they are used as probes in 
cloning, blotting procedures, and in applications such as 
?uorescence in situ hybridiZation (FISH). Homopyrimidine 
PNAs are used for strand displacement in homopurine 
targets. The restriction sites that overlap With or are adjacent 
to the D-loop are not cleaved by restriction enZymes. Also, 
the local triplex inhibits gene transcription. Thus in binding 
of PNAs to speci?c restriction sites Within a DNA fragment, 
cleavage at those sites can be inhibited. Advantage can be 
taken of this in cloning and subcloning procedures. Labeled 
PNAs are also used to directly map DNA molecules. In 
effecting this, PNA molecules having a ?uorescent label are 
hybridiZed to complementary sequences in duplex DNA 
using strand invasion. 
PNAs have further been used to detect point mutations in 
PCR-based assays (PCR clamping). PCR clamping uses 
PNA to detect point mutations in a PCR-based assay, e.g., 
the distinction betWeen a common Wild type allele and a 
mutant allele, in a segment of DNA under investigation. A 
PNA oligomer complementary to the Wild type sequence is 
synthesiZed. The PCR reaction mixture contains this PNA 
and tWo DNAprimers, one of Which is complementary to the 
mutant sequence. The Wild type PNA oligomer and the DNA 
primer compete for hybridiZation to the target. HybridiZa 
tion of the DNA primer and subsequent ampli?cation Will 
only occur if the target is a mutant allele. With this method, 
one can determine the presence and exact identity of a 
mutant. 
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Considerable research is being directed to the application 
of oligonucleotides and oligonucleotide analogs that bind 
complementary DNA and RNA strands for use as 
diagnostics, research reagents and potential therapeutics. 
PCT/EP/01219 describes novel peptide nucleic acid (PNA) 
compounds Which bind complementary DNA and RNA 
more tightly than the corresponding DNA. Because of these 
binding properties as Well as their stability, such PNA 
compounds ?nd many uses in diagnostics and research 
reagents uses associated With both DNA and RNA. With 
complementary DNA and RNA they can form double 
stranded, helical structures mimicking double-stranded 
DNA, and they are capable of being derivatiZed to bear 
pendant groups to further enhance or modulate their binding, 
cellular uptake, or other activity. 
Thus, such oligomers and compositions comprising them 
are greatly desired. 
SUMMARY OF THE INVENTION 
One aspect of the present invention provides compounds 
of formula (I): 
(I) 
Wherein: 
R8 is H or an amine protecting group; 
R9 is H, alkyl having from 1 to about 12 carbon atoms, or 
alkenyl having from 2 to about 12 carbon atoms; 
one of R4 and R5 is H and the other of R4 and R5 is a 
moiety of formula (II) 
<11) 
CH2 
Wherein 
R10 is an amine protecting group; 
L is selected from the group consisting of hydrogen, 
hydroXy, (C1—C4)alkanoyl, naturally occurring nucleobases, 
non-naturally occurring nucleobases, aromatic moieties, 
DNA intercalators, nucleobase-binding groups, and hetero 
cyclic moieties, reporter ligands, Wherein amino groups are, 
optionally, protected by amino protecting groups; 
A is a group of formula (IIa)—(IId): 
R1 R1 
R2 I R2 5 
(HA) 
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-continued 
(IIb) 
R1 R1 X | | || 
C Y C C— 
12 l2 5 
(He) 
R1 R1 R3 X | | | || 
C Y C N—C— 
l2 12 S 
(IId) 
T1 l1 I T3 
C Y C C—N— 
l2 12 5 
Where: 
X is O, S, Se, NR3, CH2 or C(CH3)2; 
Y is a single bond, O, S or NR4 Where R4 is as described 
above; 
each r and s is Zero or an integer from 1 to 5; 
each R1 and R2 is independently selected from the group 
consisting of hydrogen, (C1—C4)alkyl Which may be 
hydroXy- or alkoXy- or alkylthio-substituted, hydroXy, 
alkoXy, alkylthio, amino and halogen; and 
R3 is selected from the group consisting of hydrogen, 
(C1—C4)alkyl, hydroXy- or alkoXy- or alkylthio-substituted 
(C1—C4)alkyl, hydroXy, alkoXy, alkylthio and amino. 
BRIEF DESCRIPTION OF THE FIGURES 
The numerous objects and advantages of the present 
invention can be better understood by those skilled in the art 
by reference to the accompanying FIG. 1, Which shoWs a 
representative synthetic scheme for compounds having for 
mula 
DETAILED DESCRIPTION OF THE 
INVENTION 
Speci?c sequence recognition of DNA or RNA is of 
increasing importance for the development of biological 
probes and neW reagents for use in research (Uhlmann, E., 
Peyman, A., Chem. Rev., 1990, 90, 544, and Helene, C., 
Toulme, J. 1., Biochim. Biophys. Acta., 1990, 1049, 99). 
Peptide nucleic acids (PNA), achiral analogs of DNA in 
Which the nucleobases or nucleobase analogs are attached to 
a (2-aminoethyl)-glycine backbone through a methylene 
carbonyl linker, have properties making them Well suited for 
use as biological probes and other applications. PNAs have 
shoWn strong binding af?nity and speci?city to complemen 
tary DNA, sequence speci?c inhibition of DNA restriction 
enZyme cleavage and site speci?c in vitro inhibition of 
translation (Egholm, M., et.al., Chem. Soc, Chem. 
Commun., 1993, 800; Egholm, M., et.al., Nature, 1993, 365, 
566; Nielsen, M., et.al. Nucl. Acids Res., 1993, 21, 197; and 
Hanvey, J. C., et.al., Science, 1992, 258, 1481). Modi?ca 
tions of PNA include eXtended backbones (Hyrup, B., et.al. 
Chem. Soc, Chem. Commun., 1993, 518), extended linkers 
betWeen the backbone and the nucleobase, reversal of the 
amido bond (Lagriffoul, P. H., et.al., Biomea'. Chem. Lett., 
1994, 4, 1081), and the use of a chiral backbone based on 
alanine (Dueholm, K. L, et.al., BioMea'. Chem. Lett., 1994, 
4, 1077). 
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The present invention is directed to PNAs Which bear a 
histidine-containing moiety. Preferred compounds are those 
having formula (I): 
(I) 
Wherein 
R8 is H or an amine protecting group; 
R9 is H, alkyl having from 1 to about 12 carbon atoms, or 
alkenyl having from 2 to about 12 carbon atoms, preferably 
an allyl group; 
one of R4 and R5 is H and the other of R4 and R5 is a 
moiety of formula (II) 
(II) 
15 
6 
-continued 
(IId) 
1 R1 X R3 | | || | 
C Y C C—N— 
12 12, 
Where: 
X is O, S, Se, NR3, CH2 or C(CH3)2; 
Y is a single bond, O, S or NR4 Where R4 is as described 
above; 
each r and s is Zero or an integer from 1 to 5; 
each R1 and R2 is independently selected from the group 
consisting of hydrogen, (C1—C4)alkyl Which may be 
hydroXy- or alkoXy- or alkylthio-substituted, hydroXy, 
alkoXy, alkylthio, amino and halogen; and 
CH; 25 
>\‘ R3 is selected from the group consisting of hydrogen, 
R1°— /N (C1—C4)alkyl, hydroXy- or alkoXy- or alkylthio-substituted 
— a , roX,a oX,a t1oan ammo. C1 C4 lkyl hyd y lk y lkyl h' d ' 
30 
wherein While not Wishing to be bound by any particular theory, 
R10 is an amine protecting group; such compounds are believed to have enhanced uptake 
L is Selected from the group Consisting of hydrogen, properties. is knOWn in the art the introduction Of 
hydroxy, (C1—C4)a1kanoyl, naturally occurring nucleobases, 35 positive charges on the backbone can increase cellular 
non-naturally occurring nucleobases, aromatic moieties, uptake. The histidine moiety is capable of a partial positive 
DNA intercalators, nucleobase-binding groups, and hetero- charge at physiological pH, 
cyclic moieties, reporter ligands, Wherein amino groups are, 
0Pt10~naHY> Protected by ammo protectmg groups; Alkyl groups according to the invention include but are 
AIS a group of formula (Ha)_(Hd)' 40 not limited to straight chain, branched chain, and cyclic 
(Ha) hydrocarbons such as methyl, ethyl, propyl, pentyl, 
1 1 isopropyl, 2-butyl, isobutyl, 2-methylbutyl, and isopentyl 
If If moieties having 1 to about 12 carbon atoms, preferably 1 to 
bout 7 carbon atoms. c Y c 45 a 
l | 
R2 I R2 5 Aryl groups according to the invention are aromatic 
(11b) groups including, for eXample, benZyl, imidaZolyl, naphthyl, 
R1 R1 X phenyl, pyridyl, pyrimidinyl, and Xylyl groups and substi 
| I 50 tuted derivatives thereof, particularly those substituted With 
(I: Y (I: C_ alkyl, alkoXy, amino, and nitro groups. Preferred aryl groups 
R2 R2 5 have 6 to about 14 carbon atoms. 
(11C) . . . . . . 
1 1 3 55 The term amino acid as used herein is intended to include 
If If If T? all naturally-occurring and synthetic amino acids knoWn in 
C Y C N_C_ the art. In general, amino acids have structure H2N—CH |2 |2 (RC)—C(O)OH Where RC is the amino acid side chain. 
R I R s Representative, naturally-occurring side chains are shoWn in 
Table 1. 
TABLE 1 
CH3— CH3—CH2—S—CH2—CH2— 
HO—CH2— HO—CH2—CH2— 
C6H5—CH2— CH3—CH2(OH)— 
6,107,470 
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TABLE 1-continued 
Preferred side chains include those that exhibit polarity such 
as those having primary or secondary amines. A more 
preferred list includes HO—CH2—, HO—C6H5—CH2—, 
H02C—CH(NH2)—CH2—S—S—CH2—, HO—CH2— 
Nucleotide bases according to the invention include het 
erocyclic bases, including those Which occur naturally in 
DNA and RNA, and modi?ed bases. Modi?ed bases are 
those in Which the purine or pyrimidine ring is altered. 
Naturally occurring bases include adenine, guanine, 
hypoXanthine, Xanthine, uracil, cytosine, and thymine. 
Exemplary modi?ed bases include 6-methylaminopurine, 
7-methylguanine, and S-methylcytosine. 
As indicated in FIG. 1, compounds of formula (IV) may 
be prepared by incorporating an amino acid protecting group 
into compounds of formula 
VN 
(V) 
O 
Protecting groups are knoWn per se as chemical functional 
groups that can be selectively appended to and removed 
from functionality, such as amine, carboXyl, or hydroXyl 
groups, Which present in a chemical compound, thus ren 
dering such functionality inert to chemical reaction condi 
35 
45 
55 
65 
tions to Which the compound is eXposed. See, e.g., Greene 
and Wuts, Protective Groups in Organic Synthesis, 2d 
edition, John Wiley & Sons, NeW York, 1991. Representa 
tive carboXyl protecting groups include loWer (i.e., C1—C7) 
alkyl esters and benZyl esters. Preferred carboXyl protecting 
groups are those that are stable to moderately strong acid but 
can be removed With strongly acidic conditions. 
Compounds having formula (IV) preferably are prepared 
by appending amine protecting groups directly to amino 
acids having formula Suitable protecting groups in this 
regard include the allyloXycarbonyl (Alloc), benZyloXycar 
bonyl (CBZ) and chlorobenZyloXycarbonyl groups. Some 
preferred amine protecting groups include 
t-butyloXycarbonyl (Boc), t-butyloXymethyl, ?uorenyl 
methoXycarbonyl (Fmoc), 2,4-dinitrophenyl and isonicoti 
nyloXycarbonyl (i-Noc) groups. Preferred amine protecting 
groups for direct attachment to amino acids are those that are 
stable to acidic conditions but can be removed under basic 
conditions. 
Compounds of formula (V) can be readily obtained by 
alkylation of the corresponding amino acid, according to 
methods knoWn to those skilled in the art. For eXample, 
compounds Wherein R2 is methyl may be prepared by 
methylation, using knoWn methylating agents such as 
(trimethysilyl)diaZomethane. Other methods include alkyla 
tion With diaZomethane or preparation of the sodium salt of 
the carboXyl group folloWed by treatment With methyl 
iodide. 
PNAs of the present invention are useful as research 
reagents and as diagnostic tools. PNAs have been used in 
studies to discriminate betWeen fully complementary and 
single base mismatch targets (Orum, H., et.al., NucleicAcia's 
Research, 1993, 21, 5332—5336). The method utiliZes the 
properties of PNA e.g. higher thermal stability, greater 
speci?city When bound to complementary nucleic acid 
sequences than the corresponding deoXyribooligonucle 
otides and that PNAs are not recogniZed by DNA poly 
merase as primers. A PNA/DNA complex can effectively 
block the formation of a PCR product When the PNA is 
targeted against the PCR primer site. This method is effec 
6,107,470 
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tive in blocking target sequences When tWo target sequences 
in the same assay differ by only one base pair. Compounds 
of the present invention having greater speci?city than 
normal PNA are Well suited for use in diagnostic assays of 
this type. 
The following examples are merely illustrative of the 
present invention and should not be considered limiting of 
the scope of the invention in any Way. These examples and 
equivalents thereof Will become more apparent to those 
skilled in the art in light of the present disclosure and the 
accompanying claims. The disclosures of each patent, patent 
application, and publication cited or described in this docu 
ment are hereby incorporated herein by reference in their 
entirety. In the folloWing examples, all numbers Within 
parentheses refer to FIG. 1. 
EXAMPLE 1 
Not-Fmoc-H-benZyloxymethyl-L-histidine methyl 
ester (2) 
To Not-Fmoc-H-benZyloxymethyl-L-histidine (Sigma 
Chemical Company, 9.0 gm, 18.1 mmol) in DMF (150 mL) 
Was added (trimethylsilyl)diaZomethane (20 mL, 40 mmol/ 
2.0 M/T The mixture Was stirred under an atmosphere 
of nitrogen for about 12 hours. The solvent Was removed 
under reduced pressure to give the title compound (2) as an 
oil. The oil Was used as is for the next step Without further 
puri?cation. 
EXAMPLE 2 
H-BenZyloxymethyl-L-histidine methyl ester (3) 
To Na-Fmoc-H-benZyloxymethyl-L-histidine methyl 
ester (2) (hoW much) in dichloromethane (100 mL) Was 
added Piperidine (2.0 mL, 20 mmol). The mixture Was 
stirred under an atmosphere of nitrogen for 3 hours. The 
mixture Was concentrated under reduced pressure. The resi 
due Was diluted With methanol (50 mL) and the pH Was 
adjusted to 7.0 With HCl. Filtration yielded the title com 
pound (3) as an oil. The oil Was used as-is for the next step 
Without further puri?cation. 
EXAMPLE 3 
H-BenZyloxymethyl-L-histidine methyl ester (4) 
To H-BenZyloxymethyl-L-histidine methyl ester (3) in 
methanol (200 mL) Was added sodium cyanoborohydride 
(5.65 gm, 90 mmol). The pH of the mixture Was adjusted to 
betWeen 5 and 6 using acetic acid. Boc-aminoacetaldehyde 
(5.54 gm, 35.0 mmol) in methanol (15 mL) Was added and 
the mixture Was stirred under an atmosphere of nitrogen for 
1 hour. An additional amount of Boc-aminoacetaldehyde 
(14.4 gm, 91.3 mmol) in methanol (50 mL) Was added With 
stirring for another 12 hours. The mixture Was concentrated 
under reduced pressure. The residue Was diluted With ethyl 
acetate (500 mL) and Washed With aqueous sodium bicar 
bonate (2><200 mL). The organic phase Was dried over 
magnesium sulfate, ?ltered, and then concentrated under 
reduced pressure to give a residue. The oil Was further 
puri?ed by silica gel ?ash column chromatography using 
ethyl acetate/methanol/hexanes (5 :1:5) as the eluent to give 
5.33 g (68%) of the title compound as an oil. 
1H NMR (CDCl3) 6 1.43 (s, 9H), 1.718 (6x, 1H, NH), 
2.55 (m, 2H), 2.71 (m, 2H), 2.99 (m, 2H), 3.11 (m, 2H), 3.53 
(t, 1H), 3.68 (s, 3H), 4.42 (s, 2H), 4.80 (bs, 1H, NH), 5.33 
(S, 2H), 6.88 (s, 1H), 7.31 (m, 5H) and 7.48 (s, 1H). 
MS-FAB in negative mode, (Calc.); Found: (432.5); 431.1. 
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EXAMPLE 4 
Not-(N-Boc-2-aminoethyl)H-benZyloxymethyl-L 
histidine methyl ester (5) 
To H-BenZyloxymethyl-L-histidine methyl ester (4) (5 .33 
gm, 12.3 mmol) in DMF (100 mL) and dichloromethane (50 
mL) Was added N,N-diisopropylethylamine (3.5 mL, 25 
mmol) and thymin-1-yl-acetic acid (1.75 gm, 9.5 mmol). 
After stirring at room temperature for 20 minutes PyBrop 
(8.85 gm, 19 mmol) Was added and the mixture Was stirred 
for an additional 12 hours under an atmosphere of nitrogen. 
The solvent Was removed under reduced pressure and the 
residue Was puri?ed by silica gel ?ash column chromatog 
raphy using hexanes/methanol/ethyl acetate (4:1:5) as the 
eluent to give 1.5 (20%) of the title compound. 
Proton NMR Was consistent With structure. 
EXAMPLE 5 
Not-(N-Boc-2-aminoethyl)H-benZyloxymethyl-L 
histidine (6) 
To Not-(N-Boc-2-aminoethyl)H-benZyloxymethyl-L 
histidine methyl ester compound (5) (1.5 gm, 2.5 mmol) in 
methanol (100 mL) Was added sodium hydroxide (0.8 gm, 
20 mmol). The mixture Was alloWed to stand for 12 hours 
and the solvent Was removed under reduced pressure. The 
residue Was puri?ed by silica gel ?ash column chromatog 
raphy using ethyl acetate/methanol (4:1) as the eluent to give 
1.1 g (75%) of the title compound. 
Proton NMR Was consistent With structure. MS-FAB in 
negative mode, (Calc.); Found: (584.6); 582.6. 
EXAMPLE 6 
Not-(N-Boc-2-aminoethyl)H-benZyloxymethyl-D 
histidine (D-6) 
FolloWing the procedures illustrated in examples 1—5, and 
starting With Not-Fmoc-H-benZyloxymethyl-D-histidine 
(Sigma Chemical Company, 9.0 gm, 18.1 mmol) the D 
isomer Was synthesiZed. 
Proton NMR Was consistent With structure. MS-FAB in 
negative mode, (Calc.); Found: (584.6); 582.1. 
Various modi?cations of the invention, in addition to 
those described herein, Will be apparent to those skilled in 
the art from the foregoing description. Such modi?cations 
are intended to fall Within the scope of the appended claims. 
What is claimed is: 
1. A compound of formula: 
Wherein: 
R8 is H or an amine protecting group; 
R9 is H or alkyl having from 1 to about 12 carbon atoms 
or alkenyl having from 2 to about 12 carbon atoms; 
one of R4 and R5 is H and the other of R4 and R5 is a 
moiety of formula (II) 
6,107,470 
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-continued 
<11) 
VN 
(IId) 
Where: 
X is O, S, Se, NR3, CH2 or C(CH3)2; 
Y is a single bond, O, S or NR4 Where R4 is as 
described above; 
10 
Wherein 
R10 is an amine protecting group 
L is selected from the group consisting of hydrogen, 
hydroXy, (C1—C4)alkanoyl, naturally occurring 
nucleobases, non-naturally occurring nucleobases, 
arornatic rnoieties, DNA intercalators, nucleobase 
binding groups, and heterocyclic rnoieties, reporter 
ligands, Wherein amino groups are, optionally, pro 
tected by amino protecting groups; 
A is a group of formula (IIa)—(IId): 
(Ha) 
R1 R1 
R2 I R2 S 
R1 R1 X 
I I II (I: Y (I: c— 
R2 I R2 5 
(11b) 
(11c) 
15 
25 
35 
each r and s is Zero or an integer from 1 to 5; 
each R1 and R2 is independently selected from the 
group consisting of hydrogen, (C1—C4)alkyl Which 
may be hydroXy- or alkoXy- or alkylthio 
substituted, hydroXy, alkoXy, alkylthio, amino and 
halogen; and 
R3 is selected from the group consisting of hydrogen, 
(C1—C4)alkyl, hydroXy- or alkoXy- or alkylthio 
substituted (C1—C4)alkyl, hydroXy, alkoXy, alky 
lthio and amino. 
2. The compound of claim 1 Wherein R8 is selected from 
the group consisting of allyloXycarbonyl, 
benZyloXycarbonyl, t-butyloXycarbonyl, 
?uorenylrnethyloXycarbonyl, isonicotinyloXycarbonyl 
groups. 
3. The compound of claim 1 Wherein R9 is alkyl having 
1 to about 7 carbon atoms. 
4. The compound of claim 1 Wherein R10 is selected from 
the group consisting of t-butyloXycarbonyl, 
t-butyloXyrnethyl, ?uorenylrnethyloXycarbonyl, 2,4 
dinitrophenyl and isonicotinyloXycarbonyl groups. 
5. The compound of claim 1 Wherein R10 is benZyloXyrn 
ethyl. 
6. The compound of claim 1 Wherein L is a nucleobase. 
* * * * * 
